HomeAI · summaries
Storia in 3 fonti
Jazz bets on epilepsy again by acquiring Actio for $820M upfront
Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met for its ultra-rare epilepsy drug.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal
Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.
- ·
endpoints.news
Jazz bets on epilepsy again by acquiring Actio for $820M upfront
Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met for its ultra-rare epilepsy drug.
